Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemoradiotherapy and PBSC Transplant for Non-Hodgkin's Lymphoma
NCT00002697Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 1995
- Primary completion
- Jun 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifosfamide, carboplatin and etoposide in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Efficacy of mobilization and Efficacy of reinduction. Started Sep 1995; status: completed.
02
Drugs
ifosfamidecarboplatinetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002697.